CABENUVA Cabotegravir / Rilpivirine 400 mg - 600 mg Injection 2 mL - 2 mL

Features

• CABENUVA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine
• Requires Refrigeration
• Intramuscular (IM) gluteal
• More …

Strength

Volume